Therapeutic efficacy of combined blockade of CTLA-4 +/- PD-L1 +/- IDO is associated with re-activation of T cells directly within the tumor microenvironment

Ähnliche Einträge

• Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment
  von: Spranger, Stefani, et al.
  Veröffentlicht: (2014)
• Agonist anti-4-1BB plus neutralizing anti-CTLA-4 or -PD-L1 synergize to promote tumor regression by rescuing dying dysfunctional CD8+ T cells within the tumor microenvironment
  von: Horton, Brendan, et al.
  Veröffentlicht: (2015)
• Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4 and PD-L1 in mice with brain tumors
  von: Wainwright, Derek A., et al.
  Veröffentlicht: (2014)
• Agonistic 4-1bb antibodies in combination with inhibitory antibodies against CTLA-4, PD-L1 or LAG-3 ACT on CD8+ T cells in the tumor microenvironment and synergize to promote regression of established tumors
  von: Horton, Brendan, et al.
  Veröffentlicht: (2014)
• Up-Regulation of PD-L1, IDO, and T(regs) in the Melanoma Tumor Microenvironment Is Driven by CD8(+) T Cells
  von: Spranger, Stefani, et al.
  Veröffentlicht: (2013)